144 related articles for article (PubMed ID: 11786656)
1. Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.
Sánchez-Silos RM; Pérez-Giraldo C; Blanco MT; Morán FJ; Hurtado C; Gómez-García AC
Chemotherapy; 2001 Dec; 47(6):415-20. PubMed ID: 11786656
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
Schick DG; Canawati HN; Montgomerie JZ
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
[TBL] [Abstract][Full Text] [Related]
3. [Antibiotic susceptibility analysis of Enterococcus spp. isolated from urine].
Rudy M; Nowakowska M; Wiechuła B; Zientara M; Radosz-Komoniewska H
Przegl Lek; 2004; 61(5):473-6. PubMed ID: 15515808
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
5. [Study of a cohort of patients with Enterococcus spp. Bacteraemia. Risk factors associated to high-level resistance to aminoglycosides].
García-Vázquez E; Albendín H; Hernández-Torres A; Canteras M; Yagüe G; Ruiz J; Gómez J
Rev Esp Quimioter; 2013 Sep; 26(3):203-13. PubMed ID: 24080886
[TBL] [Abstract][Full Text] [Related]
6. [Enterococci as uropathogens. Frequency of isolation and sensitivity to antibacterial agents].
Guirguitzova B; Chankova D; Zozikov B; Minkov N
Ann Urol (Paris); 1998; 32(1):15-9. PubMed ID: 9559070
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children.
McNeeley DF; Eckert SJ; Noel GJ
Pediatr Infect Dis J; 2000 Jul; 19(7):675-6. PubMed ID: 10917238
[No Abstract] [Full Text] [Related]
9. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Zhanel GG; Karlowsky JA; Hoban DJ
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
[TBL] [Abstract][Full Text] [Related]
11. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
Coque TM; Singh KV; Murray BE
J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Jones RN; Beach ML; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):247-52. PubMed ID: 9884844
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of high level aminoglycoside and vancomycin resistance among enterococci in Turkey.
Cirak MY; Sultan N
Acta Microbiol Pol; 1998; 47(3):267-73. PubMed ID: 9990710
[TBL] [Abstract][Full Text] [Related]
15. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
Zinner SH; Gilbert D; Dudley MN
Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
[TBL] [Abstract][Full Text] [Related]
17. [Multicenter trial of Enterococcus antibiotic susceptibility].
Sidorenko SV; Rezvan SP; Grudinina SA; Krotova LA; Sterkhova GV
Antibiot Khimioter; 1998; 43(9):9-18. PubMed ID: 9791681
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
